CD274 and non-small cell lung carcinoma: In conclusion, we report a four‐case series of patients with advanced NSCLC and poor PS whose tumor had a high PD‐L1 expression level (TPS ≥50%), and only one case with a very high expression level (TPS 100%) responded to pembrolizumab.